Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Pharmacokinetics and safety of subcutaneous vs intravenous human normal immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
- Disease:Chronic inflammatory demyelinating polyradiculoneuropathy
- Substances:Human Normal Immunoglobulin
Poland- Participants:18–64 years · 65+ years
- Substances:Human Normal Immunoglobulin
- Sponsor:Grifols Therapeutics LLC













